Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Drug-resistant TB news

Show

From To
Rise of superbug tuberculosis hampers global control efforts

Rising rates of superbug tuberculosis (TB) are threatening to derail decades of progress against the contagious disease, experts said on Thursday, and new drugs powerful enough to treat them are few and far between.

Published
23 March 2017
From
Reuters
TB partners, patients ask: How does a bacterium responsible for nearly a third of drug-resistance deaths not make list of R&D priority pathogens?

While the unveiling of a list highlighting the need to fund drug development against specific pathogens represented just a beginning for some antimicrobial resistance fighting efforts, the list represented a setback for TB drug development, advocates say.

Published
02 March 2017
From
Science Speaks
Three-drug regimen beats XDR-TB in first trial

A regimen of three oral drugs given for six months was enough to clear extensively drug-resistant tuberculosis (XDR-TB) in 29 of the first 31 people to have

Published
17 February 2017
By
Keith Alcorn
New tuberculosis therapy could be more potent than current treatments

Taking a new approach toward tuberculosis therapy, a UCLA-led research team has devised a potential drug regimen that could cut the treatment time by up to 75 percent, while simultaneously reducing the risk that patients could develop drug-resistant TB.

Published
26 January 2017
From
UCLA
Public Health Groups Welcome Johns Hopkins University and Medicines Patent Pool Agreement for Development of Promising New TB Drug

While deal marks a critical step in the fight against TB, health groups warn that the deal lacks safeguards that would ensure worldwide affordability.

Published
26 January 2017
From
MSF Access Campaign
The Medicines Patent Pool Announces First Licence for Tuberculosis Treatment

The Medicines Patent Pool today announced that it has signed a licence with Johns Hopkins University to facilitate the clinical development of tuberculosis (TB) drug candidate sutezolid. The antibiotic sutezolid has long been considered a promising investigational treatment that, if further developed in combination with other drugs, could be used to more effectively treat both drug-sensitive and drug-resistant TB in patients.

Published
25 January 2017
From
Medicines Patent Pool
Indian Woman Wins Right to Use Last-Resort Tuberculosis Drug

An 18-year-old woman and her family have won a battle in an Indian court to gain access to a restricted tuberculosis drug that her doctors say she needs to survive.

Published
24 January 2017
From
Wall Street Journal (blog)
Person-to-person contact may cause most drug-resistant TB cases

The worst form of drug-resistant tuberculosis isn't just arising from inadequate treatment, it's mostly being spread from person to person, according to a new study of hundreds of cases in South Africa.

Published
23 January 2017
From
Reuters
Early data indicates new regimen represents reprieve for patients with XDR TB

Data from an ongoing trial presented today indicates patients with extensively drug resistant tuberculosis for whom other treatments had failed, showed signs of full recovery from disease following a six-month regimen of two new tuberculosis drugs and one repurposed drug.

Published
31 October 2016
From
Science Speaks
Final data backs early findings, WHO recommendations, showing shorter MDR TB treatment course working better

Presenting results today of a nine month treatment regimen that led to an 82 percent cure rate among 1006 patients with multidrug-resistant tuberculosis, researchers called their findings a breakthrough that can support countries in adopting shorter, more effective and potentially less damaging treatment for TB that is resistant to more than one first line treatment.

Published
26 October 2016
From
Science Speaks

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.